4-1BB receptor Agonist - Pipeline Insight, 2024

This “4-1BB receptor Agonist - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in 4-1BB receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

4-1BB receptor Agonist: Understanding

4-1BB receptor Agonist: Overview

Human (h)4-1BB (TNFRSF9, CD137) is a tumor necrosis factor receptor (TNFR)2 superfamily (TNFRSF) member that contains four cysteine-rich domains (CRD) in the N-terminal extracellular region connected to a C-terminal cytoplasmic region that contains a TNF receptor-associated factor (TRAF)-binding motif to initiate subsequent signaling (1). 4-1BB acts as a co-stimulatory molecule on activated T cells to enhance their response to antigen and can also aid activation of other cells such as NK cells. The ligand of h4-1BB, h4-1BBL (TNFSF9, CD137L), is a member of the TNF ligand superfamily expressed on activated antigen-presenting cells such as B cells, dendritic cells, and macrophages. h4-1BBL can also be expressed extracellularly as a soluble homotrimer. Binding of 4-1BBL to 4-1BB results in aggregation of several receptors that allows for the efficient recruitment of TRAF adapter proteins such as TRAF1 and -2 to the cytoplasmic TRAF-binding motifs of separate 4-1BB receptors, ultimately initiating co-stimulatory signaling. On T cells and NK cells, 4-1BB signaling can inhibit apoptosis while augmenting proliferation and effector functions such as cytokine production or CTL activity that can lead to eradication of established tumors. Although the antitumor properties have made 4-1BB an ideal target for cancer immunotherapy, 4-1BB signaling can also induce anti-inflammatory effects augmenting regulatory activity in T cells and dendritic cells, suggesting it is also a potential target for the treatment of autoimmune diseases.

“4-1BB receptor Agonist - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the 4-1BB receptor Agonist pipeline landscape is provided which includes the disease overview and 4-1BB receptor Agonist treatment guidelines. The assessment part of the report embraces, in depth 4-1BB receptor Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, 4-1BB receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence 4-1BB receptor Agonist R&D. The therapies under development are focused on novel approaches to treat/improve 4-1BB receptor Agonist.

4-1BB receptor Agonist Emerging Drugs Chapters

This segment of the 4-1BB receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

4-1BB receptor Agonist Emerging Drugs

Utomilumab: PfizerUtomilumab (PF-05082566) is an investigational immunotherapy and is a fully human IgG2 monoclonal antibody (mAb). The 4-1BB (CD-137) protein receptor is found on certain T cells (primarily on CD8+, but also on CD4+ memory T cells) and natural killer (NK) cells. Based on preclinical data, when utomilumab (PF-05082566) binds to 4-1BB, it has been observed to stimulate and increase the number of immune cells. The hypothesis is that this may help augment enhanced anti-tumor immune function. Preclinical studies suggest that combining utomilumab (PF-05082566) with a checkpoint inhibitor, such as anti-PD-1/anti-PD-L1, or other immunotherapies may amplify the immune response.

Urelumab: Bristol Myers SquibbUrelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors. Urelumab targets the extracellular domain of CD137. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. It is currently being investigated in Phase II stage of development for the treatment of Solid tumors.

ADG106: AdageneADG106, is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb being developed for the treatment of advanced solid tumors and non-Hodgkin’s lymphoma. CD137 stimulates the immune system to attack cancer cells and is a key driver for long-lasting T-cell proliferation and survival. Clinical trials of ADG106 as monotherapy have been conducted in the US and China. A trial in combination with toripalimab is underway in China, and one in combination with pembrolizumab is planned. In January 2022, Adagene announced first patient with advanced Non-Small Cell Lung Cancer Dosed in Phase I/II clinical trial of ADG106 in Combination with Nivolumab in Singapore.

AGEN2373: Agenus Inc.AGEN2373 is a fully human monoclonal antibody designed to boost the immune response to cancer cells by enhancing CD137 co-stimulatory signaling in activated immune cells. The unique binding properties of AGEN2373 are expected to limit its activity outside of the tumor site and mitigate toxicities that may be associated with systemic activation of CD137 in humans. AGEN2373 has demonstrated preliminary clinical benefit and has been well tolerated without signs of liver toxicity, an adverse event that has impacted competitor antibodies in the clinic. Gilead currently has an exclusive option to license AGEN2373. Agenus retains the right to opt-in to share Gilead’s development and commercialization costs in the United States in exchange for a 50:50 profit share and US co-commercialization rights.

4-1BB receptor Agonist: Therapeutic Assessment

This segment of the report provides insights about the different 4-1BB receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in 4-1BB receptor Agonist

There are approx. 25+ key companies which are developing the therapies for 4-1BB receptor Agonist. The companies which have their 4-1BB receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Pfizer.

Phases

This report covers around 28+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

4-1BB receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

4-1BB receptor Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 4-1BB receptor Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 4-1BB receptor Agonist drugs.

4-1BB receptor Agonist Report Insights

• 4-1BB receptor Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

4-1BB receptor Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing 4-1BB receptor Agonist drugs?
• How many 4-1BB receptor Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of 4-1BB receptor Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the 4-1BB receptor Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for 4-1BB receptor Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Agenus
• Bristol Myers Squibb
• Pfizer
• Adagene
• Compass Therapeutics
• ABL Bio
• F-star Therapeutics
• Merus
• Chugai Pharmaceuticals
• Lyvgen Biopharma
• Inhibirix
• Genmab
• Bicycle Therapeutics
• Apogenix
• Numab Therapeutics
• Crescendo Biologics
• Alligator Bioscience
• Hanmi Pharmaceutical
• Shanghai Huaota Biopharmaceutical
• Molecular Partners AG
• Hoffman-La-Roche
• Pieris Pharmaceuticals
• SystImmune
• Eucure Biopharma

Key Products

• AGEN2373
• Urelumab
• Utomilumab
• ADG106
• CTX-471
• ABL503
• ABL111
• FS120
• LVGN6051
• MCLA-145
• INBRX-105
• GEN 1046
• BT7401
• GEN1042
• NM21-1480
• CB307
• BT7480
• BT7455
• ALG.APV-527
• ATOR-1017
• BH3120
• HOT-1030
• MP0310
• FS222
• RG 7827
• PRS 344
• YH004

This product will be delivered within 1-3 business days.